Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
Koiji SasakiHagop M KantarjianTapan Mahendra KadiaKeyur PatelSanam LoghaviGuillermo Garcia ManeroElias J JabbourCourtney D D DiNardoNaveen PemmarajuNaval G DaverIman Abou DalleNicholas James ShortMusa YilmazPrithviraj BoseKiran NaqviSherry PierceFevzi YalnizJorge E CortesFarhad RavandiPublished in: Cancer (2019)
The addition of sorafenib improves survival in patients with FLT3-ITD-mutated AML regardless of whether they undergo allogeneic stem cell transplantation.